This page shows how Foundayo coverage works across major insurers, what prior authorization typically requires, and what changes are coming in 2026. Compare coverage across BCBS, UnitedHealthcare, Aetna, Cigna, Medicare, Medicaid, TRICARE, and more.
COVERAGE OVERVIEW
Is Foundayo Covered by Insurance?
Short answer: It depends on your plan. Foundayo was FDA-approved on April 1, 2026; some PBMs and insurers have since added it (for example, CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026), but many plans still exclude weight-loss drugs. Expect similar barriers to other GLP-1 medications: large employer plans are most likely to cover, many marketplace plans exclude weight-loss drugs, and basic Medicare Part D coverage excludes them by law, but people with eligible Part D coverage can get Foundayo through the Medicare GLP-1 Bridge, which runs outside Part D ($50 per monthly fill, with conditions including prior authorization).
- NEW DRUG: Foundayo (orforglipron) was FDA-approved April 1, 2026—some plans' policies are still forming
- MOST LIKELY: Large employer plans (43% of firms with 5,000+ workers covered GLP-1s for weight loss in 2025)
- LESS LIKELY: ACA marketplace plans; basic Medicare Part D coverage excludes weight-loss drugs, but the Medicare GLP-1 Bridge, which runs outside Part D, covers Foundayo for $50 per monthly fill (with conditions)
- IF DENIED: Over 65% of appeals succeed with proper documentation
Best for: Employer plans, ACA marketplace, Medicare, Medicaid, TRICARE.
The best price for Foundayo is $25/fill — requires insurance coverage
With commercial coverage, the Foundayo savings card can bring the cost to as little as $25 (up to $100 per fill, $1,000 a year, 10 fills) (commercial insurance only), compared with LillyDirect self-pay of $149–$299/month. Denied? You can appeal, and 65%+ succeed.
Haven't applied for coverage?
Use the insurer directory below to see how your plan handles GLP-1 coverage. Since Foundayo is new, expect similar policies to Zepbound/Wegovy.
Jump to insurer directory ↓Then find your fastest path to approval →Denied Foundayo coverage?
65%+ of appeals succeed with proper documentation.[5] Don't give up.
Get help with your appeal →✓ Free case review · ✓ Could save $1,500+/year vs LillyDirectKey Coverage Facts
- Foundayo is new. FDA-approved April 1, 2026—some insurers haven't published Foundayo-specific policies yet. Expect similar barriers to other GLP-1s.
- Only 16% of firms with 200–999 workers covered GLP-1 medications for weight loss in 2025—rising to 43% of the largest employers (5,000+ workers)[2]
- Expect prior authorization—the commercial weight-loss policies we checked (for example, UnitedHealthcare’s 2026 P 1114-23 and Aetna’s 6450-C) require your doctor to get approval before you can fill it[1][9]
- Basic Medicare Part D coverage excludes weight loss drugs by federal statute—but Foundayo is covered for weight loss through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) for $50 per monthly fill, if you meet CMS’s eligibility criteria[8]
- Medicaid: 13 states (as of January 2026) covered GLP-1s for obesity, with policies evolving—the CMS BALANCE model’s Medicaid track is voluntary for states, and no participating state has been confirmed[4]
Coverage by Plan Type
| Plan Type | Coverage | Key Notes |
|---|---|---|
| Large employer (5,000+) | Most likely | 43% of firms with 5,000+ workers cover GLP-1s for weight loss (2025); PA expected |
| Small/mid employer (200+) | Less likely | 16% of firms with 200–999 workers cover GLP-1s for weight loss (2025) |
| ACA Marketplace | Check plan | Varies by plan and state; many exclude weight-loss drugs |
| Medicare Part D | Bridge: $50 per monthly fill | Basic Part D coverage excludes weight-loss drugs by law; Foundayo is covered through the Medicare GLP-1 Bridge, which runs outside Part D (July 1, 2026 – December 31, 2027), with conditions |
| Medicaid | Varies by state | 13 states (as of January 2026) covered GLP-1s for obesity |
If Denied, You Can Appeal
Over 65% of prior authorization appeals succeed when patients appeal—yet fewer than 12% ever file an appeal.[5] If your Foundayo coverage is denied, don't give up. See what to do after a denial →
Looking for Step-by-Step Help?
This page shows which insurers cover GLP-1 medications (including Foundayo). For guidance on how to navigate PA, appeals, and get approved, see our How to Get Foundayo Covered by Insurance.
Bottom line: Foundayo just launched—coverage policies are still forming. Use the insurer directory below to understand how your plan typically handles GLP-1 coverage, and if denied, remember that you can appeal. Next step: Look up how your insurer handles coverage below.
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
Insurer Directory
Find Your Insurance Company
Select your insurer below to see how they typically handle GLP-1 coverage. Since Foundayo is newly approved (April 2026), specific policies are still being finalized—expect similar requirements to Zepbound and Wegovy.
Coverage Policies Still Forming
Foundayo was just FDA-approved on April 1, 2026. Most insurers haven't announced formal Foundayo-specific policies yet. The coverage statuses below reflect general GLP-1 handling by each insurer—always verify current status with your specific plan.
Blue Cross Blue Shield
Varies by StateCoverage varies significantly by state and plan. Most require PA with BMI (Body Mass Index) ≥30 or ≥27 + comorbidity and lifestyle documentation. Check your plan’s Foundayo criteria.
View BCBS Coverage →UnitedHealthcare / OptumRx
Plan-DependentEmployer and individual plans vary. When covered, typically requires PA + lifestyle documentation. UHC’s weight-loss PA policy (2026 P 1114-23) includes Foundayo, where your plan covers weight-loss drugs.
View UHC Coverage →Aetna
PA RequiredPrior authorization required for GLP-1s. Policies require BMI documentation, lifestyle modification, and may have step therapy requirements. Check your plan’s Foundayo criteria.
View Aetna Coverage →Cigna / Express Scripts
PA RequiredPrior authorization required with state variations. Check if Foundayo is added to your specific formulary—policies still forming for this new drug.
View Cigna Coverage →CVS Caremark
Varies by PlanCVS Caremark ended its new-to-market block on Foundayo on June 1, 2026, where plans have approved it for coverage. Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize). Check your own plan’s formulary.
View CVS Caremark Coverage →Anthem Blue Cross
Varies by PlanCoverage varies by state and plan type. Many commercial plans exclude GLP-1s for weight loss; some employer plans cover with PA. Verify your specific formulary.
Detailed guide coming soonKaiser Permanente
Very LimitedCoverage depends on your Kaiser region and plan, including whether your employer added weight-loss drug coverage. Check your plan's drug list for Foundayo.
Detailed guide coming soonHumana
Medicare & MedicaidHumana no longer sells employer-group commercial medical plans (exit completed in 2025). Humana Medicare Advantage (MA-PD) and Part D members can use the Medicare GLP-1 Bridge for Foundayo, with conditions. Medicaid varies by state.
Detailed guide coming soonACA Marketplace Plans
State-DependentCoverage varies by plan and state. ACA plans follow state mandates and insurer policies. Many exclude weight loss drugs; those that cover them may require PA.
View Marketplace Coverage →Medicare Part D
Bridge: $50 per monthly fillBy law, basic Part D coverage excludes drugs used for weight loss, but Foundayo is covered through the Medicare GLP-1 Bridge, which runs outside Part D (July 1, 2026 – December 31, 2027), for $50 per monthly fill, if you have eligible Part D coverage, meet CMS’s eligibility criteria and your prescriber gets prior authorization.
View Medicare Details →Medicaid
Varies by State13 states (as of January 2026) covered GLP-1s for weight loss under fee-for-service Medicaid. CMS BALANCE Model (Medicaid): Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed.
View Medicaid Coverage →TRICARE
Plan-DependentPrime & Select may cover weight-loss GLP-1s with PA (criteria: BMI ≥30, or ≥27 with a weight-related condition, after a lifestyle program and trials of other weight-loss drugs). TRICARE For Life lost weight-loss drug coverage on August 31, 2025. Active duty members pay no pharmacy copays.
Detailed guide coming soonOther Plans
What if My Insurer Isn't Listed?
If your insurance company isn't listed above, here's what to do:
Check Your Formulary
Look up "Foundayo" or "orforglipron" on your plan's formulary (drug list). Since Foundayo is brand new, it may not appear yet—check back in 30-60 days or call your plan.
Call Your PBM
Your pharmacy benefit manager—the company that manages drug coverage for your insurer (phone number is on your prescription card)—can confirm coverage, PA requirements, and step therapy rules.
Review Your SPD
Your Summary Plan Description (the legal document explaining your benefits) lists all exclusions. Search for "obesity," "weight loss," or "anti-obesity medications."
Self-Funded Employer Plans
If your employer self-funds their health plan (pays claims directly instead of through an insurer), they have full discretion over coverage. Your plan may cover Foundayo even if the insurer's standard plans don't—or vice versa. Contact HR or your benefits administrator.
Related Guides
Explore Other Foundayo Coverage Resources
Need more than just insurer-specific info? These guides cover the full coverage landscape.
COVERAGE OUTLOOK
What's Changing in 2026
2026: Diverging Trends
The insurance landscape for GLP-1s is splitting: Medicare covering Foundayo through the Medicare GLP-1 Bridge while many commercial plans are pulling back. Here's what to watch for Foundayo.
Most recent policy review: April 2026
Government Programs: What's Changing
Foundayo and the CMS BALANCE Model
On December 23, 2025, CMS launched the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth)—a voluntary pilot program to expand GLP-1 access through negotiated pricing. Foundayo (orforglipron) is on CMS's list of BALANCE drugs:[7]
- Medicare GLP-1 Bridge: Live now (July 1, 2026 – December 31, 2027). Foundayo is a Bridge drug: eligible Part D enrollees pay $50 per monthly fill.[8]
- BALANCE in Medicare Part D: Delayed, with no new start date
- Medicaid: Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed
- Bridge eligibility: Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD
Check CMS.gov/BALANCE for updates.
Medicare Part D: Current Status
Basic Medicare Part D coverage excludes drugs used for weight loss (the Treat and Reduce Obesity Act has not been enacted), but the Medicare GLP-1 Bridge covers Foundayo:[8]
Medicare and weight-loss GLP-1s: the Medicare GLP-1 Bridge
Through the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027), a temporary CMS demonstration that runs outside the Part D benefit, people with eligible Part D coverage can get Wegovy, Foundayo or the Zepbound KwikPen for weight loss for $50 a month, if they meet CMS’s eligibility criteria and their prescriber gets prior authorization.
- Who qualifies: Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD.
- Who doesn’t: Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026.
- Cost: $50 per monthly fill. Does not count toward the Part D deductible or out-of-pocket cap. Extra Help (LIS) does not lower it. Not eligible for the Medicare Prescription Payment Plan. Coupons and discount programs can’t be applied.
- No opt-in needed: Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization.
- If it’s denied: No appeals process for a Bridge prior-authorization denial: your prescriber can resubmit with more information (Part D appeal rights for Part D coverage decisions still apply).
Source: CMS, Medicare GLP-1 Bridge · Facts in this box verified October 5, 2026
- Part D out-of-pocket cap: $2,100 in 2026 ($2,400 in 2027) for covered Part D drugs (the Bridge’s $50 doesn’t count toward it)
- BALANCE in Part D: Delayed, with no new start date
Medicaid Coverage: State-by-State
13 states (as of January 2026) covered at least one GLP-1 for weight management under fee-for-service Medicaid. GLP-1s for type 2 diabetes are covered separately.[4]
- California (Medi-Cal): Medi-Cal stopped covering GLP-1s for weight loss on January 1, 2026. Wegovy can still be approved for MASH or cardiovascular disease, Zepbound for sleep apnea, and members under 21 can still get coverage with PA (EPSDT).[10]
- BALANCE Model (Medicaid): Voluntary for states, which can join between May 2026 and January 1, 2027; no participating state has been confirmed
Verify coverage directly with your state Medicaid program, as policies change frequently.
Commercial Insurance: Tightening Coverage
Many Plans Dropping or Restricting GLP-1 Coverage (Jan 2026)
Effective January 1, 2026, several insurers dropped or restricted GLP-1 coverage for weight loss, limiting it to type 2 diabetes or plans with explicit weight management benefits:[11]
- Health New England: Dropped Wegovy, Zepbound, and Saxenda coverage for individual and small group members effective January 1, 2026
- Fallon Health: Community Care plans no longer cover weight loss medications as of January 1, 2026
- Blue Cross Blue Shield of Massachusetts: Blue Cross Blue Shield of Massachusetts excludes Saxenda, Wegovy and Zepbound from January 1, 2026 (employers can buy a rider)
- CVS Caremark: From July 1, 2025 to September 30, 2026, Zepbound was nonpreferred or excluded on CVS Caremark’s most common commercial formularies, with Wegovy preferred; Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize). CVS Caremark ended its new-to-market block on Foundayo on June 1, 2026[12]
Self-funded employers can still negotiate to include Foundayo coverage—check with your HR or benefits administrator about your specific plan.
Employer Coverage Trends
Despite cost concerns, most large employers with existing GLP-1 coverage plan to continue it:
- About 90% of larger employers currently covering GLP-1s planned to keep coverage in 2026, according to an employer survey reported by HR Executive[13]
- 44% of employers with 500+ employees covered weight loss medications in 2024 (Mercer)[14]
- 64% of employers with 20,000+ employees covered them in 2024—the largest employers are most likely to cover[14]
- Cost impact: In EBRI's simulations, covering GLP-1s raised employer premiums by about 5–14% (5.3% to 13.8%), which drives some employers to add restrictions[15]
Note: All 2026 timelines, pricing, and coverage expansions are subject to federal rulemaking, final CMS implementation, and individual state/employer decisions. Verify with your specific plan.
What Should You Do Now?
- Verify your 2026 benefits: Confirm whether your employer plan will cover Foundayo—call HR or your benefits administrator
- Consider plan switching: If your current plan excludes GLP-1s, evaluate other options during open enrollment
- Medicare patients: Ask your prescriber about the Medicare GLP-1 Bridge—Foundayo for $50 per monthly fill if you meet CMS’s eligibility criteria
- Start documentation now: Even before formal coverage is announced, document your BMI history, failed interventions, and comorbidities
- Need financial help? With commercial coverage, the Foundayo Savings Card can bring the cost to $25 a fill; Lilly Cares doesn't list Foundayo (Foundayo cost help)
FOUNDAYO INSURANCE COVERAGE
Frequently Asked Questions
It depends on your plan. Foundayo (orforglipron) was FDA-approved on April 1, 2026, and some plans' policies are still forming. Based on GLP-1 coverage patterns, large employer plans are most likely to cover (43% of firms with 5,000+ workers covered GLP-1s for weight loss in 2025). Some BCBS, UHC, Aetna, and Cigna plans cover GLP-1s with prior authorization. Many marketplace plans exclude weight loss drugs, and basic Medicare Part D coverage excludes them by law—but Foundayo is covered through the Medicare GLP-1 Bridge, which runs outside Part D (July 1, 2026 – December 31, 2027), for $50 per monthly fill, with conditions.
Your best bet is a large employer plan. In 2025, 43% of firms with 5,000+ workers covered GLP-1s for weight loss—compared to 16% of firms with 200–999 workers (KFF). Per Mercer, 64% of employers with 20,000+ employees covered them in 2024. Many marketplace plans don't cover weight-loss drugs; on Medicare, the path for weight loss is the Medicare GLP-1 Bridge (with conditions). Even with coverage, expect to need prior authorization.
Yes, with conditions, through the Medicare GLP-1 Bridge, a temporary CMS program that runs outside your Part D benefit. By law, basic Part D coverage excludes drugs used for weight loss, but the Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers Foundayo for $50 per monthly fill if you have eligible Part D coverage and meet CMS’s eligibility criteria. Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization. Note: The December 2024 OSA approval applies to Zepbound (tirzepatide), not Foundayo—Foundayo has no OSA coverage pathway.
Medicaid coverage varies by state. 13 states (as of January 2026) covered GLP-1 medications for obesity under fee-for-service Medicaid. Note: Medi-Cal stopped covering GLP-1s for weight loss on January 1, 2026. The CMS BALANCE Model’s Medicaid track is voluntary for states; no participating state has been confirmed.
In the policies we checked, yes. The commercial weight-loss policies we checked (UnitedHealthcare, Aetna) require prior authorization. Insurers typically request BMI documentation, evidence of weight-related medical conditions, lifestyle program participation, and sometimes prior treatment history before approving coverage. Since Foundayo is brand new, some plans may take time to establish formal PA criteria.
Many insurers classify GLP-1s as weight-loss medications, which are excluded under many pharmacy benefit designs. Since Foundayo is new (approved April 1, 2026), it may not be on your plan’s formulary yet even if the plan covers other GLP-1s. Additionally, several insurers (including Health New England and Fallon Health) dropped GLP-1 coverage for weight loss entirely effective January 2026.
Yes. If your employer self-funds its health plan (common at large companies), they have authority to add Foundayo coverage even if the insurer's standard plans exclude it. In an employer survey reported by HR Executive, about 90% of larger employers covering GLP-1s planned to keep coverage in 2026. Your HR or benefits administrator can confirm your specific plan's coverage—and may be able to advocate for adding Foundayo.
No, not for Foundayo. The December 2024 OSA (obstructive sleep apnea) approval applies to Zepbound (tirzepatide), not Foundayo. Foundayo is only FDA-approved for chronic weight management—it has no OSA indication. If you have sleep apnea and want the OSA coverage pathway, ask your doctor about Zepbound instead.
Insurance Coverage for Other GLP-1s
Coverage varies significantly by medication. Compare your options:
References
- UnitedHealthcare. (2026). "Pharmacy Clinical Program: Weight Loss (2026 P 1114-23, effective October 1, 2026)." Includes Foundayo where the plan covers weight-loss drugs. uhcprovider.com
- Kaiser Family Foundation / Peterson-KFF Health System Tracker. (October 2025). "2025 Employer Health Benefits Survey" and "Perspectives from Employers on GLP-1 Coverage." In 2025, 16% of firms with 200–999 workers, 30% with 1,000–4,999 and 43% with 5,000+ workers covered GLP-1s primarily for weight loss. https://www.healthsystemtracker.org/brief/perspectives-from-employers-on-the-costs-and-issues-associated-with-covering-glp-1-agonists-for-weight-loss/
- U.S. Food and Drug Administration. (April 1, 2026). FDA approval of Foundayo (orforglipron) for chronic weight management in adults with obesity or overweight with comorbidities. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
- Kaiser Family Foundation. (2024). "Medicaid Coverage of and Spending on GLP-1s." Tracking of state Medicaid GLP-1 coverage policies. https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/
- Kaiser Family Foundation. (January 2025). "Medicare Advantage Prior Authorization Determinations (2023)." 81% of MA appeals succeed; we use a conservative 65%+ estimate for commercial insurance. https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2023/
- American Medical Association. (2024). "Over 80% of prior auth appeals succeed." https://www.ama-assn.org/practice-management/prior-authorization/over-80-prior-auth-appeals-succeed-why-aren-t-there-more
- Centers for Medicare & Medicaid Services. (December 23, 2025). "CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines and Promote Healthier Living." Announcement of the BALANCE Model; the CMS BALANCE page lists Foundayo among the model's drugs. https://www.cms.gov/priorities/innovation/innovation-models/balance
- Kaiser Family Foundation. (March 2026). "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid." Explains the Medicare GLP-1 Bridge and the BALANCE Model, including eligibility and included medications. https://www.kff.org/medicare/issue-brief/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
- Aetna. (2026). "Weight Loss (BMI 35) GIP/GLP-1, GLP-1 Agonists PA with Limit, policy 6450-C." Lists Foundayo with prior authorization criteria. aetna.com
- California Department of Health Care Services. (January 2026). "Changes to GLP-1 Drug Coverage – Effective January 1, 2026." Medi-Cal restrictions on GLP-1 coverage for weight loss. https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/member/GLP1_Changes.pdf
- Health New England. "GLP-1 Medication Update." healthnewengland.org; Fallon Health. "Changes to weight loss drug coverage starting January 1, 2026." fallonhealth.org; Blue Cross Blue Shield of Massachusetts. "GLP-1 medications for obesity: coverage update." bluecrossma.com
- Massachusetts Group Insurance Commission / Mass.gov. (October 2025). "CVS Caremark decides to remove Zepbound from CVS Caremark formulary." Zepbound removed effective July 1, 2025; Wegovy preferred alternative. https://www.mass.gov/news/cvs-caremark-decides-to-remove-zepbound-from-cvs-caremark-formulary
- HR Executive. (December 2025). "Emerging GLP-1 drugs are reshaping employers' 2026 priorities." About 90% of larger employers plan to continue covering GLP-1s; 86% of mid-market employers. https://hrexecutive.com/emerging-glp-1-drugs-are-reshaping-employers-2026-priorities/
- Mercer. (2025). "GLP-1 considerations for 2026: Your questions answered." In 2024, 44% of employers with 500+ employees covered weight loss medications; 64% of those with 20,000+ employees. https://www.mercer.com/en-us/insights/us-health-news/glp-1-considerations-for-2026-your-questions-answered/
- Employee Benefit Research Institute. (October 2025). "GLP-1 Coverage and Its Impact on Employment-Based Health Plan Premiums." In EBRI's simulations, covering GLP-1s raised premiums by 5.3% to 13.8%. https://www.ebri.org/content/glp-1-coverage-and-its-impact-on-employment-based-health-plan-premiums--a-simulation-based-analysis
- Eli Lilly Investor Relations. (November 2025). "Lilly and U.S. Government Agree to Expand Access to Obesity Medicines." Medicare beneficiaries will pay no more than $50/month for Zepbound and orforglipron. https://investor.lilly.com/news-releases/news-release-details/lilly-and-us-government-agree-expand-access-obesity-medicines
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.